Company Description
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
| Country | Hong Kong |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,988 |
| CEO | Dr. Wei-Guo Su B.Sc., Ph.D. |
Contact Details
Address: 48th Floor, Cheung Kong Center, 2 Queen's Road Central Hong Kong, K3 00000 Hong Kong | |
| Phone | 852-2121-3888 |
| Website | hutch-med.com |
Stock Details
| Ticker Symbol | HCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001648257 |
| CUSIP Number | 44842L103 |
| ISIN Number | US44842L1035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chi Keung To ACGI, B.Sc., M.B.A. | Executive Chairman |
| Dr. Wei-Guo Su B.Sc., Ph.D. | Chief Executive Officer, Chief Scientific Officer and Executive Director |
| Chig Fung Cheng BEc, CA | Chief Financial Officer and Executive Director |
| Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E | Company Secretary and Non-Executive Director |
| Dr. Karen Jane Atkin | Executive Vice President and Chief Operating Officer |
| David Ng | Head of Investor Relations and Capital Strategies |
| Charles George Rupert Nixon | Group General Counsel |
| Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management and Communications |
| Selina Zhang | Senior Vice President of Global Human Resources |
| Dr. Qingmei Wang Ph.D. | Senior Vice President of Business Development and Strategic Alliances |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 6-K | Report of foreign issuer |
| Mar 14, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 7, 2024 | 6-K | Report of foreign issuer |